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Up-Regulation of Endothelial Delta-like 4 Expression Correlateswith
Vessel Maturation in Bladder Cancer
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Abstract Purpose: Angiogenesis and vascular endothelial growth factor (VEGF) expression are associat-
edwith apooroutcome inbladder cancer.Tounderstandmore about themechanisms,we studied
the role of delta-like 4 (DLL4), an endothelial-specific ligand of the Notch signaling pathway, in
bladder cancer angiogenesis.
Experimental Design:The expression of DLL4, CD34, and VEGF were studied in a cohort of
60 bladder tumors and 10 normal samples using quantitative PCR. In situ hybridization was
used to study the pattern of DLL4 expression in 22 tumor and 9 normal samples. Serial sec-
tions were also stained for CD34 and a-smooth muscle actin (a-SMA) using conventional im-
munohistochemistry.
Results: The expression of DLL4 was significantly up-regulated in superficial (P < 0.01) and
invasive (P < 0.05) bladder cancers. DLL4 expression significantly correlated with CD34
(P < 0.001) and VEGF (P < 0.001) expression. The in situ hybridization studies showed that
DLL4 was highly expressed within bladder tumor vasculature. Additionally, DLL4 expression
significantly correlated with vessel maturation as judged by periendothelial cell expression of
a-SMA, 98.7% of DLL4-positive tumor vessels coexpressed a-SMA, compared with 64.5% of
DLL4-negative tumor vessels (P < 0.001). High DLL4 expression may have prognostic value in
superficial and invasive bladder.
Conclusion:DLL4 expression is associated with vascular differentiation in bladder cancer; thus,
targeting DLL4 may be a novel antiangiogenic therapy.
Bladder cancer results in over 13,000 deaths per year in the
United States alone. Despite advances in the management
of bladder cancer, the need for new treatment modalities
remains. As with most solid tumors, bladder cancer growth
andmetastatic progression is dependent on the acquisition of an
adequate blood supply through the process of angiogenesis (1).
The role of angiogenesis in bladder cancer has been extensively
studied ever since Chodak et al. (2) showed that urine from
patients with bladder cancer contained proangiogenic growth
factors (3).
The Notch signaling pathway has recently been shown to play
an important role in angiogenesis (4–6). It is an evolutionarily
conserved signaling pathway involved in cell fate determination,
cellular differentiation, proliferation, survival, and apoptosis
(7–9). In mammalian cells, it comprises five transmembrane
Notch ligands (Jagged1, Jagged2, DLL1, DLL3, and DLL4) and
four Notch receptors (Notch1-4). Ligand receptor binding leads
to the cleavage and subsequent translocation from the cell
membrane to the nucleus of the Notch intracellular domain
(10, 11). In the nucleus, theNotch intracellular domain interacts
with the transcription factor CSL to regulate the transcription
of the basic helix-loop-helix proteins hairy/enhancer of split
(HES) and HES-related protein (HEY; refs. 12–14).
Delta-like 4 (DLL4) is an endothelial-specific ligand
expressed at sites of vascular development and angiogenesis
(15, 16). DLL4 expression has previously been shown to be
up-regulated within the vasculature of breast and renal tumors.
In utero DLL4 knockout mice die of severe vascular defects, and,
interestingly, haploinsufficiency of DLL4 also results in
embryonic lethality from severe vascular defects (15, 17, 18).
Similar haploinsufficiency phenotypes for angiogenic pathways
have only been previously described for vascular endothelial
growth factor (VEGF) knockout mice (19, 20). In human
endothelial cells, we have recently shown that DLL4 plays an
important role in regulating endothelial cell proliferation,
migration, survival, and network formation (21).
In this study, we have investigated the expression of DLL4 in
transitional cell carcinoma of the bladder, studied the role of
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DLL4 in vessel maturation, and carried out an initial evaluation
of the role of DLL4 in prognosis.
Materials andMethods
Tissue samples. Human bladder tissue was obtained postoperatively
from the Department of Urology, Churchill Hospital, Oxford, United
Kingdom. All patients gave signed, informed consent for their tissues to
be used for scientific research. Ethical approval for the study was
obtained from the Clinical Ethics Committee, Oxford Radcliffe
Hospitals NHS Trust, Oxford, United Kingdom.
Tumor samples were obtained following either transurethral
resection (TURBT) or radical cystectomy. Bladder cancers were staged
using the tumor-node-metastasis classification (22). Tumor samples
were divided into three groups depending on their stage: Ta tumors, T1
superficial tumors (Ta and T1 tumors were collectively designated as
superficial tumors), and T2-4 invasive tumors. For the quantitative PCR
(qPCR) analysis, a cohort of 10 normal bladder samples and 60 bladder
tumors were studied. Areas of normal bladder and tumor were
identified at cytoscopy, excised, and snap frozen in liquid nitrogen.
For the in situ hybridization/immunohistochemistry vessel counting
study, the series comprised six Ta (TURBT), six T1 (TURBT), six T2-4
(TURBT), and four T2-4 (cystectomy) samples. Truly normal full
thickness bladder sections were difficult to source, so microscopically
normal areas within radical cystectomy specimens (four samples) and
normal ureters (five samples) obtained following organ donation were
used to represent ‘‘normal tissue.’’
RNA extraction and reverse transcription. Total RNA from frozen
tissue samples was extracted after morselizing in liquid nitrogen and
homogenizing in TRI-Reagent (Sigma-Aldrich, St. Louis, MO). The
quality of RNA extracted was assessed using RNA 6000 Nano Chips and
the Agilent 2100 Bio-analyzer (Agilent Technologies, Paulo Alto, CA).
cDNA was synthesized by reverse transcribing total RNA using the High
Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA).
Real-time qPCR. Real-time qPCR and analysis was done using the
method previously described by Patel et al. (21). Human b-actin was
used as a reference gene to normalize for differences in the amount of
total RNA in each sample. Primer/probe kits were purchased as Assays-
on-Demand from Applied Biosystems: DLL4, VEGF, and CD34 .
Relative quantitation of gene expression was done using the method
described by Pfaffl (23). The normal bladder sample with the median
expression of h-actin was designated the comparator.
In situ hybridization. Radioactive in situ hybridization was done
on paraffin-embedded tissue sections by the in situ hybridization
service, Cancer Research UK London Research Institute, following a
method described by Poulsom et al. (24). The probe used to detect
DLL4 was a 741 bp fragment located from position 1,775 to 2,516
bp (16). After 14 days, sections were visualized using a Nikon Eclipse
ME600 dark field microscope, an Optronics digital camera, and
Magnafire Version 2.0.
Immunohistochemistry. Paraffin-embedded tissue blocks were serially
sectioned 4 Am in thickness, dewaxed, and rehydrated in serial alcohol
washes. Endogenous peroxidase activity was blocked with 0.03%
hydrogen peroxide (20 minutes). Double immunostaining for CD34
and a-smooth muscle actin (a-SMA) was done by sequentially adding
CD34 primary antibody 1:200 for 30 minutes (Novocastra, Newcastle-
upon-Tyne, United Kingdom, QBEnd/10), DAKO (Carpinteria, CA)
Checkmate EnVision Detection kit (peroxidase/3,3¶-diaminobenzidine-
rabbit/mouse, K5007) for 30 minutes, 3,3¶-diaminobenzidine substrate
for 2 minutes, a-SMA primary antibody 1:1,000 for 30 minutes (DAKO-
1A4), Envision AP Polymer 30 minutes, and Vector Blue substrate for 6
minutes. Sections were mounted using Aquamount.
Analysis of DLL4, CD34, and a-SMA expression in bladder
cancer . DLL4 (in situ hybridization) and CD34/a-SMA (immunohis-
tochemistry) expression in serial sections was quantified. First, the
distribution of DLL4 expression was assessed by two observers (N.P.
and M.D.). Twenty random fields within the DLL4 in situ sections were
scanned using a light microscope at a magnification of 100 and
assessed for the presence of any DLL4-positive vessels. Second, tissues
were further analyzed by identifying the two to three areas of highest
DLL4 expression. These areas were photographed at 100 magnifica-
tion using a Nikon Eclipse ME600 dark field microscope, an Optronics
digital camera, and Magnafire version 2.0. The equivalent areas were
identified upon the serial sections and captured accordingly. The digital
images were then used to quantify the vasculature for CD34, a-SMA,
and DLL4 .
Statistics. Data are presented as mean F SE. Statistical analysis was
done using GraphPad Prism. Tests used included t test, one-way
ANOVA, Mann-Whitney and m2 tests. Statistical significance was
concluded when P < 0.05 and is denoted in the figures with an asterisk.
Table 1. Patient demographics for the qPCR bladder cancer samples
Normals Ta T1 T2 T3-4 Superficials Invasives Tumors
Number 10 11 32 11 6 43 17 60
Mean age (y) 76.4 71.0 71.2 69.5 68.3 71.2 69.1 70.57
Age range (y) 68-87 62-82 42-89 56-83 46-91 42-89 46-91 42-91
Sex
M 10 9 25 10 4 34 14 48
F 0 2 7 1 2 9 3 12
Operation Cystoscopy
and biopsy
TURBT TURBT TURBT T3 (5) = TURBT;
T4 (1) = CYST


































Abbreviations: CYST, cystectomy; DXT, radiotherapy; BCG, bacille Calmette Gue´rin; MMC, mitomycin C; Nil, no further treatment; N/A,
not applicable.
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Results
Quantitative analysis of DLL4 expression in bladder cancer
using qPCR. Quantitative PCR was used to study gene
expression in a cohort of bladder tumors and normal bladder
samples (Table 1). Relative gene expression was assessed using
the method of Pfaffl (23), a modified method of comparative
quantitation. In this technique, the expression of DLL4 was
calculated relative to the reference gene b-actin . The expression
of b-actin was equivalent between the normals and tumors
(b-actin expression normals: median C t = 23.0, range 22.1-23.8,
n = 10; b-actin expression tumors: median C t = 22.8, range
22.0-23.8, n = 60, P = 0.3).
The relative expression of DLL4 was significantly elevated
in bladder tumors compared with normal bladders (mean
DLL4 expression in tumors = 4.5 F 0.4, n = 60; mean
expression of DLL4 in normal samples = 2.4 F 0.2, n = 10,
P = 0.01). In comparison to normal tissue, DLL4 expression
was noted to be highest in superficial tumors (mean
expression = 4.7 F 0.6, n = 43, P < 0.05) followed by
invasive tumors (mean expression = 3.9 F 0.6, n = 17, P >
0.05; Fig. 1A).
Quantitative PCR was done for the endothelial marker CD34
to determine if the differences in DLL4 expression were simply
due to differences in vascular density between normal and
tumor samples. The relative expression of CD34 was highest in
the normal samples (mean expression = 1.2 F 0.2, n = 10)
when compared with superficial (mean expression 0.6 F 0.1,
n = 43) and invasive tumors (mean expression = 0.5 F 0.1,
n = 17; Fig. 1B).
A ratio of DLL4 expression to CD34 expression (DLL4/CD34
ratio) was calculated by dividing the relative expression of
DLL4 by that of CD34 . The mean DLL4/CD34 ratio for normal
samples was 3.2 F 1.2, for superficial tumors was 10.6 F 1.0
(P < 0.001), and for invasive tumors was 9.1 F 4.0 (P < 0.001;
Fig. 1C). The expression of DLL4 correlated significantly
with the expression of CD34 in tumors (Spearman rank
correlation coefficients: all tumors = 0.6, n = 60, P < 0.001;
superficial tumors = 0.6, n = 47, P < 0.001; invasive tumors =
0.6, n = 13, P < 0.05), but not in normal bladder tissue controls
(normal samples = 0.2, P > 0.05; Fig. 1D).
The expression of VEGF was also assessed using qPCR. The
mean expression of VEGF in both superficial and invasive
tumors was significantly higher than in normal bladder tissue
Fig. 1. Analysis of DLL4, CD34, and
VEGF expression using qPCR. A, DLL4
expressionwas significantly up-regulated in
superficial bladder cancer compared with
normal bladder tissue. B, the expression of
CD34 was significantly higher in the normal
tissues than in the bladder tumors. C, the
DLL4/CD34 ratio was significantly higher in
superficial and invasive bladder cancer
compared with normal tissue.D, DLL4
expression was significantly correlated with
CD34 expression in bladder tumors
(Spearman rank correlation coefficient =
0.6, P < 0.001, n = 60). E,VEGF expression
was significantly elevated in both superficial
and invasive bladder cancer. F, the
expression of DLL4 significantly correlated
withVEGF expression (Spearman rank
correlation coefficient = 0.4, P = 0.001,
n = 60. *, P < 0.05; **, P < 0.01;
***, P < 0.001). Bars, SE.
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(44.6 F 5.3 and 45.9 F 13.6 versus 4.0 F 1.0; P < 0.001;
Fig. 1E). The Spearman rank correlation coefficient of VEGF
and DLL4 expression was significant only for superficial
tumors (Spearman rank correlation coefficients all tumors =
0.4, P = 0.001, n = 60; superficial tumors = 0.4, P < 0.01, n =
43; invasive tumors = 0.3, P = 0.3, n = 17; normals = 0.4,
P > 0.3, n = 10; Fig. 1F).
DLL4 mRNA expression pattern. In situ hybridizationwas used
to assess the pattern of DLL4 mRNA expression in a series of 22
bladder cancers, 4 normal bladders, and 5 normal ureters. The
expression ofDLL4 was compared with that of the pan-endothelial
marker CD34. Like CD34, DLL4 expression was confined to the
vascular endothelium,unlikeCD34; however,DLL4 expressionwas
only noted within a subset of vessels (Fig. 2A).
Fig. 2. DLL4, CD34, and a-SMA
expression in bladder cancer. A, in situ
hybridization was used to study the pattern
of DLL4 expression in bladder cancer. Serial
sections were also stained for CD34 and
a-SMA using conventional double
immunohistochemistry.Vessels in the
suburothelial layer of normal ureter were
predominantly microvessels staining only
for CD34 (black arrows).Vessels within
superficial and invasive bladder tumors
stained positive for CD34 (blackarrow) and
for a-SMA (blue arrows). DLL4 expression
was confined to the vascular endothelium.
Endothelial expression of DLL4 is shown in
the light (red arrows) and dark field
(green arrows) in situ hybridization.
Quantitation studies of the expression of
DLL4, CD34, and a-SMAwere done at
100 magnification. B, representative
fields of view. DLL4 light fields, black
autoradiographic silver grains; DLL4 dark
field, white reflections; CD34, brown
staining; a-SMA, blue staining.
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Twenty random fields within each of the 9 normal (180
fields), 12 superficial bladder tumor (240 fields), and 10
invasive bladder tumor (200 fields) sections were scored for the
presence or absence of DLL4-positive vessels (Fig. 2B). The
presence of a single DLL4-positive vessel was sufficient for a
field to be regarded as DLL4 positive (maximum score: 20 of 20
fields, minimum score: 0 of 20). Compared with normal tissue
(positive random fields 1.4 F 0.7), DLL4-positive vessels were
most abundant in superficial tumors (positive random fields
14.3 F1.2, P < 0.001) followed by invasive tumors (positive
random fields 8.0 F1.4, P < 0.05; Fig. 3A). The differences are
likely to be greater as eight of the nine normal cases had less
than two DLL4-positive random fields, with the remaining
normal case having seven DLL4-positive fields. The number of
positive cases and their distributions for each tissue group are
shown in Fig. 3B.
The expression of DLL4 was further studied by identifying
DLL4 ‘‘hotspots.’’ For each tumor, the two areas with the
highest concentration of DLL4-positive vessels were identified
and photographed using a light and dark field microscope. In
the case of normal tissue, the three most positive DLL4 areas
were photographed; in the absence of DLL4 expression,
representative photographs were taken to include both sub-
urothelial microvessels and mature stromal vessels.
The proportion of vessels positive for DLL4 within the
hotspots was higher in superficial and invasive tumor samples
compared with both normal bladder tissue and normal
ureter (mean percentage of positive hotspot vessels: normal
bladder = 0.6 F 0.4, n = 12; normal ureter = 10.5 F 5.3, n = 15;
Ta TURBT = 67.5 F 5.2, n = 12, P < 0.001, compared with
normal ureter and bladder; T1 TURBT = 70.6 F 8.0, n = 12,
P < 0.001, compared with normal ureter and bladder; T2-4
cystectomy = 24.7 F 6.7, n = 8, compared with normal ureter
and bladder; T2-4 TURBT = 70.0 F 6.8, n = 12, P < 0.001,
compared with normal ureter and bladder; Fig. 3C). Within
the invasive tumor group, DLL4 expression was noted to be
higher in the TURBT specimens than in the cystectomy
specimens although this was not statistically significant.
Coexpression of DLL4 and a-SMA. Serial sections of each
case were also stained for CD34 and a-SMA using conventional
double immunohistochemistry (Fig. 2B). The DLL4 hotspot
areas were identified within these serial sections and
corresponding matched photographs were taken.
DLL4 hotspots were studied within normal (27 fields, 9
cases) and tumor tissue (44 fields, 22 cases). Similar numbers
of vessels were present within the different tissue types (normal
bladder = 41.7 F 8.9, normal ureter 31.5 F 7.2, Ta TURBT =
52.3 F 8.0, T1 TURBT = 47.2 F 9.5, T2-4 cystectomy = 41.8 F
6.1, T2-4 TURBT = 37.6 F 4.9).
In the course of the hotspot study, a total of 3,008 vessels
were identified as staining positive for CD34. Of these vessels,
2,025 were within tumor sections (22 cases) and 983 in normal
tissue sections (9 cases). Taken as a whole, 2,403 (79.9%)
hotspot vessels showed periendothelial expression of a-SMA,
whereas 1,226 (40.8%) hotspot vessels expressed DLL4 and
589 (19.6%) vessels expressed neither (n = 31 cases). Further
evaluation showed that 1,210 of 1,226 (98.7%) of DLL4
positive vessels were also positive for a-SMA; in comparison,
only 1,193 of 1,782 (66.9%) of DLL4-negative vessels coex-
pressed a-SMA (n = 31 cases; P < 0.001, m2 test; Fig. 4A).
These data were then analyzed after subclassifying into
normal and tumor vasculature (9 normal, 22 tumor cases).
Within the normal tissue, 687 of 983 (69.9%) vessels were
positive for a-SMA. Of the normal hotspot vessels, 26 of 983
(2.6%) were DLL4 positive, 100% of which coexpressed a-
SMA. Nine hundred fifty-seven of 983 vessels were DLL4
Fig. 3. Quantitation of DLL4 in situ hybridization studies.The expression of DLL4
was studied in 20 random fields per case (10 normal, 12 superficial bladder
tumors, and10 invasive bladder tumors) using in situ hybridization.A, a significantly
higher number of random fields had DLL4-positive vessels in superficial (P < 0.001)
and invasive tumors (P < 0.05) compared with normal tissue. B, the expression
of DLL4 was uncommonwithin the normal vasculature. Eight of nine normal cases
had less than two DLL4-positive random fields; this compares to 0 of12 superficial
tumors and1of 10 invasive tumors. C, the percentage of DLL4-positive vessels
within DLL4 hotspot areas was significantly higher in superficial tumors and
invasive tumors compared with both normal bladder and ureteric tissue. Expression
of DLL4 was noted to be higher in invasiveTURBTspecimens than in invasive
cystectomy specimens. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Bars, SE.
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negative of which 661 (69.1%) also expressed perivascular a-
SMA (P = 0.001, m2 test; Fig. 4B).
Analysis of the tumor vasculature showed 1,716 of 2,025
(84.7%) vessels were a-SMA positive and 1,200 of 2,025
(59.3%) vessels were DLL4 positive. Of the 1,200 DLL4-
positive vessels, 1,184 (98.7%) also expressed a-SMA, whereas
only 532 of 825 (64.5%) DLL4-negative tumor vessels stained
positive for a-SMA (P < 0.001, m2 test; Fig. 4C). These results
indicate that DLL4 is significantly up-regulated and colocalized
together with a-SMA in the tumor vasculature.
Relation of DLL4 expression to outcome. Follow-up was
available for 39 of the 43 superficial tumors (91%) and 16 of
the 17 invasive tumors (94%). The mean duration of follow-up
for the superficial cases was 12 months (range 1-36 months,
median = 6) and for the invasive cases was 33 months (range
5-84 months, median = 23.5).
In the case of superficial cancers, the disease-free period was
measured by determining the time to first recurrence (Fig. 5A).
Kaplan-Meier curves were used to show that the median time to
recurrence for patients in whom the expression of DLL4 was
above the median was 6 months, whereas that for patients with
low levels of DLL4 was 18 months, but this was not statistically
significant.
Superficial bladder cancer is often treated with adjuvant
intravesical chemotharpy. The tumor samples used in this study
were collected when the administration of mitomycin C
immediately after TURBT was not routine practice. Of the 39
patients with superficial tumors for whom follow-up was
available, 14 subsequently received adjuvant courses of intra-
vesical therapy; 4 received mitomycin C, 8 bacille Calmette
Gue´rin, and 2 both. Of these 14 patients, 10 were noted to have
high levels of DLL4 expression.
Kaplan-Meier curves were used to assess the time to cancer-
specific death in the invasive cancers (Fig. 5B). Of the 16 patients
with available follow-up, 8 received radical radiotherapy (high
DLL4 = 4, low DLL4 = 4), 4 underwent radical cystectomies
(high DLL4 = 3, low DLL4 = 1), and 4 were treated palliatively
(high DLL4 =1, low DLL4 = 3). Patients with high DLL4 levels
had a median survival of 7.5 months compared with 44.5
months for those with low DLL4 levels (hazard ratio = 2.40).
Because of the small numbers in this study, no statistical
significance was shown upon comparison of the curves.
Discussion
The aim of this study was to evaluate DLL4 as a potential
novel antiangiogenic target in bladder cancer. Using quantita-
tive PCR, we showed that DLL4 expression is up-regulated in
transitional cell carcinoma of the bladder. Additionally,
quantitation of CD34 expression was done using qPCR as a
means of assessing sample vascular density. Interestingly, the
expression of CD34 was higher in the normal samples than in
Fig. 4. DLL4 and vessel maturation. DLL4 and a-SMA expression was analyzed
by creating m2 contingency tables. DLL4 expression was significantly
associated with a-SMA expression (P < 0.001).
Fig. 5. DLL4 as a prognostic markers. High DLL4 expression was associated
with an earlier median time to recurrence in superficial bladder cancer (A ; P > 0.05)
and earlier median time to cancer-specific death in invasive cancer (B ; P > 0.05).
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the tumor samples. These normal bladder samples were
obtained as cold cup biopsies at cytoscopy, and so contained
a high number of suburothelial microvessels. The presence of
these vessels within the normal tissues is the most likely
explanation for the high CD34 expression levels seen in the
normal samples.
In keeping with previous work (25), we showed that VEGF
mRNA expression was up-regulated in bladder cancer. In our
study, the expression of DLL4 also significantly correlated
with the expression of CD34 and VEGF in bladder cancers.
These results matched our previous findings in clear-cell renal
cell carcinoma that DLL4 expression correlated with VEGF
expression (21) and also supported in vitro studies that have
shown the regulation of DLL4 in endothelial cells by VEGF
(21, 26).
In situ hybridization was used for the first time to show that
DLL4 expression is up-regulated in bladder cancer and has an
endothelial cell–specific pattern of expression. Quantitation of
DLL4 expression was done by assessing expression within both
random fields and DLL4 hotspots. DLL4 expression within
random fields was more widespread within bladder cancer
samples than normal tissues. Further subclassification of the
tumors showed that DLL4 expression was most widespread
within the superficial cases. O’Brien et al. (27) reported that
tumor vessel formation in superficial and invasive bladder
cancers was driven by differing angiogenic pathways. Angio-
genesis in papillary-type superficial bladder tumors is associat-
ed more strongly with VEGF and results in characteristic
mature, well-defined, functional fibrovascular cores that do
not penetrate the underlying muscle (28). In invasive cancers,
new vessel formation can also arise as a result of interactions
between tumor cells and native vessels within the muscularis
layer. The production of metalloproteases disrupts the extra-
cellular matrix and liberates growth factors like basic fibroblast
growth factor (29). Vessels formed under the influence of these
varying angiogenic pathways may show differences in their
characteristics.
It is interesting to note that DLL4 expression was highest in
the TURBT samples whether superficial or invasive. The
majority of tumor tissue obtained at TURBT is from exophytic
tumors. The vessels within these areas of tumor are neo-
angiogenic tumor vessels, and most likely arise from the
suburothelial microvessels. The vasculature within the cystec-
tomy specimens, however, is composed of a combination of
neoangiogenic vessels and preexisting bladder vessels. The
difference in DLL4 expression between the cystectomy and
TURBT specimens suggests that DLL4 expression is enhanced in
neoangiogenic vessels, of which there may be more in the
TURBT samples.
Angiogenic vessels mature upon the recruitment of pericytes
(30). To understand if DLL4 played a role in vessel maturation
in human cancer, serial sections were immunostained for CD34
and a-SMA, and an assessment was made of vessel maturation
within the DLL4 hotspot areas. This is the first time that vessel
maturity has been assessed in bladder cancer. a-SMA expression
was found on nearly 70% of normal vessels and 85% of tumor
vessels studied. The vessels that lacked a-SMA expression were
most often microvascular in nature.
Vessel maturation has previously been studied in a number
of different tumor types. Eberhard et al. (31) showed that the
degree of vessel maturation was highly variable between
different tumors, in breast cancer nearly 70% of vessels were
a-SMA positive, whereas only 10% to 20% of glioblastoma and
renal cancer vessels were a-SMA positive. More recently,
confocal microscopy was used by Morikawa et al. (32) to
show that >97% of pancreatic tumor vessels expressed a-SMA
compared with 22% of normal pancreatic vessels. They also
found that a-SMA expression was absent from a significant
proportion of capillaries and microvessels within the normal
vasculature; these vessels did, however, stain for desmin,
another marker of periendothelial cells.
A highly significant association was noted between DLL4
expression and a-SMA expression in both normal and tumor
vessels. The expression of a-SMA in normal specimens was lower
in DLL4-negative vessels (normal 69%, tumor 65%) compared
with DLL4-positive vessels (normal 100%, tumor 99%). This
suggests that DLL4 may play a role in regulating vessel
maturation by interacting with Notch receptors upon pericytes.
The mechanism by which endothelial expressed DLL4
regulates vessel maturation needs further investigation. DLL4
has been shown to signal through both Notch1 and Notch4
between endothelial cells (33–35), but the effect of endothelial
DLL4 on pericytes is not reported. However, evidence that
Notch plays a role in vessel maturation comes from a number
of sources. Vessels within mice deficient for DLL4 have an
absence of smooth muscle/pericyte coverings (15). This
phenotype is similar to that of platelet-derived growth factor-
B or platelet-derived growth factor receptor-B–deficient mice
(36, 37).
The human syndrome CADASIL is a vascular disease
characterized by mutations of the Notch3 receptor leading to
abnormalities of vascular smooth muscle (4). A recent in vitro
study by Sweeney et al. (38) showed that vascular smooth
muscle cells express Notch 1, Notch 3, HES1, HES5, HEY1,
HEY2, and HEYL. They showed that inhibition of RBP-Jn
activity led to decreased proliferation, increased apoptosis, and
increased migration in vascular smooth muscle cells. Clearly,
our clinical study provides justification for more extensive
in vitro work.
Tumor vessels typically show disorganized vascular pat-
terning, which in conjunction with their abnormal ultra-
structures results in chaotic blood flow, high interstitial
pressures, and increased vessel leakiness (30). Tumor
vasculature consists of a mix of immature vessels devoid of
pericyte coverings and more mature vessels with pericyte/
smooth muscle cell coats. Endothelial cell proliferation and
sprouting have been to shown to be most prevalent within
the immature vessels, suggesting that it is these vessels that
are angiogenic (32, 39, 40). These vessels are also the ones
most susceptible to antiangiogenic therapies. Benjamin et al.
(41) studied vessel maturation in prostate cancer. They
showed that androgen blockade decreased production of
VEGF, which, in turn, led to the regression only of immature
vessels lacking pericyte coverings in prostate cancer. They
showed that almost 40% of tumor vessels were positive for
a-SMA; however, after androgen blockade, the proportion of
vessels coated with a-SMA rose to 79%.
Gee et al. (39) also found that vessels covered with a-SMA
were protected from the antiangiogenic therapy, which in their
case was interleukin-12. These findings have important
implications for the development of future antiangiogenic
therapies. Tumors that have a high proportion mature vessels
Human Cancer Biology
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are less likely to respond to for example anti-VEGF therapies, as
the pericytes seem to offer protection against growth factor
deprivation. We have recently shown in human endothelial
cells that overexpression of DLL4 inhibits proliferation by
down-regulating VEGF receptor 2 and NRP1 expression (42),
providing an additional mechanism for resistance to such
therapies. The association shown between DLL4 expression and
a-SMA expression suggests that targeting DLL4 in addition to
VEGF may, by targeting both mature and immature vessels,
prove to be of greater therapeutic benefit and we are currently
investigating this in xenograft models.
The biological function of DLL4 is not confined to vessel
maturation. Knockout studies have shown that haploinsuffi-
ciency of DLL4 results in embryonic lethality from severe
vascular defects (15, 17, 18). The demonstration of vascular
defects in heterozygous mice is uncommon and highlights
the importance of DLL4 in vascular development. Similar
phenotypes have only been described for VEGF knockout
mice (19, 20). We have recently shown that down-regulating
DLL4 expression in vitro using RNA interference significantly
inhibits endothelial cell proliferation, migration, and network
formation (21). Similarly, we have shown up-regulation of
Delta 4 expression disrupts endothelial function (42), a
phenotype previously found for Notch4, where in vivo up-
regulation or down-regulation disrupts angiogenesis (43, 44).
This implies that a narrow range of notch signaling is needed
for optimum angiogenesis. Thus, targeting DLL4 may inhibit
tumor angiogenesis by blocking multiple endothelial cell
functions.
Endothelial expression of DLL4 may represent an interme-
diate step toward final differentiation by promoting maturation
and functionality; thus, it may be an important target for
tumors resistant to anti-VEGF therapy.
Exploratory analysis of the value of DLL4 as a prognostic
marker was assessed by relating DLL4 expression with clinical
follow-up data. In superficial and invasive disease, high levels
of DLL4 conferred an increased risk of tumor recurrence or
cancer-specific death, respectively. We additionally noted that
10 of the 14 patients that received adjuvant intravesical therapy
had high levels of DLL4 expression. Adjuvant mitomycin C or
bacille Calmette Gue´rin is commonly used in superficial
bladder cancers thought to be at high risk of recurrence and
progression. The risk stratification of superficial bladder tumors
is based on the number of tumors at first presentation, number
and frequency of recurrences, and the tumor histology. In this
study, we observed for the first time that conventionally
classified high-risk tumors seemed to express high levels of
DLL4 . The intensive nature of the microscopic studies meant
that we could not examine a larger cohort; however, we are
currently trying to develop antibodies to investigate this in
much larger numbers.
Here, for the first time, we have identified DLL4 as a novel
angiogenic target in bladder cancer. We have shown that DLL4
(a) is preferentially expressed in tumor vasculature, (b) is
associated with vessel maturation, and (c) may have prognostic
value in superficial and invasive cancer. Taken with our recent
findings that an optimal level of DLL4 is necessary for
endothelial cell function (21, 42), targeting DLL4 either by
inhibition or overexpression may be an approach worthy of
further investigation in the management of superficial and
invasive bladder cancer.
Acknowledgments
We thankToby Hunt, RosemaryJeffrey, Leticia Campo, Stephen Fox, andProfes-
sor Roy Bicknell for their contributions to this work.
References
1. Folkman J. Tumor angiogenesis: therapeutic implica-
tions. NEnglJMed1971;285:1182^6.
2. Chodak GW, Scheiner CJ, Zetter BR. Urine from
patientswith transitional-cell carcinoma stimulatesmi-
gration of capillary endothelial cells. N Engl J Med
1981;305:869^74.
3. Streeter EH, Harris AL. Angiogenesis in bladder can-
cer-prognostic marker and target for future therapy.
Surg Oncol 2002;11:85^100.
4. Shawber CJ, Kitajewski J. Notch function in the vas-
culature: insights from zebrafish, mouse andman.Bio-
Essays 2004;26:225^34.
5. Iso T, Hamamori Y, Kedes L. Notch signaling in vas-
cular development. Arterioscler Thromb Vasc Biol
2003;23:543^53.
6. LiJL,HarrisAL.Notchsignaling fromtumorcells: anew
mechanismofangiogenesis.CancerCell 2005;8:1^3.
7. Artavanis-Tsakonas S, Matsuno K, Fortini ME. Notch
signaling.Science1995;268:225^32.
8.Weinmaster G. The ins and outs of notch signaling.
Mol Cell Neurosci 1997;9:91^102.
9. Radtke F, Raj K. The role of Notch in tumorigenesis:
oncogene or tumour suppressor? Nat Rev Cancer
2003;3:756^67.
10.MummJS, Kopan R. Notch signaling: from the out-
side in. Dev Biol 2000;228:151^65.
11.Weinmaster G. Notch signaling: direct or what? Curr
Opin Genet Dev1998;8:436^42.
12. Nakagawa O, McFadden DG, Nakagawa M, et al.
Members of the HRT family of basic helix-loop-helix
proteins act as transcriptional repressors downstream
of Notch signaling. Proc Natl Acad Sci U S A 2000;
97:13655^60.
13. Davis RL,Turner DL.Vertebrate hairy and Enhancer
of split related proteins: transcriptional repressors reg-
ulating cellular differentiation and embryonic pattern-
ing. Oncogene 2001;20:8342^57.
14. IsoT, Kedes L, HamamoriY. HES and HERP families:




to major defects in arterial and vascular development.
ProcNatlAcadSciUSA2004;101:15949^54.
16.Mailhos C, Modlich U, Lewis J, et al. Delta4, an en-
dothelial specific notch ligand expressed at sites of
physiological and tumor angiogenesis. Differentiation
2001;69:135^44.
17. Duarte A, Hirashima M, Benedito R, et al. Dosage-
sensitive requirement for mouse Dll4 in artery devel-
opment. Genes Dev 2004;18:2474^8.
18. Krebs LT, Shutter JR,Tanigaki K, et al. Haploinsuffi-
cient lethality and formation of arteriovenous malfor-
mations in Notch pathway mutants. Genes Dev
2004;18:2469^73.
19. Ferrara N, Carver-Moore K, Chen H, et al. Hetero-
zygous embryonic lethality induced by targeted in-
activation of the VEGF gene. Nature 1996;380:
439^42.
20. Carmeliet P, Ferreira V, Breier G, et al. Abnormal
blood vessel development and lethality in embryos
lacking a singleVEGF allele. Nature1996;380:435^9.
21. Patel NS, Li JL, Generali D, et al. Up-regulation of
y-like 4 ligand inhuman tumor vasculature and the role
of basal expression in endothelial cell function. Cancer
Res 2005;65:8690^7.
22. Sobin LH.TNM classification of malignant tumours,
6th ed. NewYork:Wiley; 2002.
23. Pfaffl MW. A new mathematical model for relative
quantification in real-time RT-PCR. Nucleic Acids Res
2001;29:e45.
24. Poulsom R, Longcroft JM, Jeffery RE, Rogers
LA, Steel JH. A robust method for isotopic ribop-
robe in situ hybridisation to localise mRNAs in rou-
tine pathology specimens. Eur J Histochem 1998;
42:121^32.
25. CrewJP, O’BrienT, BradburnM, et al.Vascular endo-
thelial growth factor is a predictor of relapse and stage
progression in superficial bladder cancer. Cancer Res
1997;57:5281^5.
26. Liu ZJ, ShirakawaT, LiY, et al. Regulation of Notch1
and Dll4 by vascular endothelial growth factor in arte-
rial endothelial cells: implications for modulating arte-
riogenesis and angiogenesis. Mol Cell Biol 2003;23:
14^25.
27. O’BrienT, Cranston D, Fuggle S, Bicknell R, Harris
AL. Different angiogenic pathways characterize su-
perficial and invasive bladder cancer. Cancer Res
1995;55:510^3.
28. CrewJP.Vascular endothelial growth factor: an im-
portant angiogenic mediator in bladder cancer. Eur
Urol 1999;35:2^8.
29. O’Brien TS, Fox SB, Dickinson AJ, et al. Expres-
sion of the angiogenic factor thymidine phosphory-
lase/platelet-derived endothelial cell growth factor
in primary bladder cancers. Cancer Res 1996;56:
4799^804.
30. Jain RK. Molecular regulation of vessel maturation.
Nat Med 2003;9:685^93.
DLL4 Expression in Bladder Cancer
www.aacrjournals.org Clin Cancer Res 2006;12(16) August15, 20064843
31. Eberhard A, Kahlert S, GoedeV, et al. Heterogeneity
of angiogenesis andblood vesselmaturation inhuman
tumors: implications for antiangiogenic tumor thera-
pies. Cancer Res 2000;60:1388^93.
32.Morikawa S, Baluk P, Kaidoh T, et al. Abnorma-
lities in pericytes on blood vessels and endothe-
lial sprouts in tumors. Am J Pathol 2002;160:
985^1000.
33. Shawber CJ, Das I, Francisco E, KitajewskiJ. Notch
signaling in primary endothelial cells. Ann N Y Acad
Sci 2003;995:162^70.
34. Rao PK, Dorsch M, ChickeringT, et al. Isolation and
characterization of the notch ligand y4. Exp Cell Res
2000;260:379^86.
35. Shutter JR, Scully S, Fan W, et al. Dll4, a novel
Notch ligand expressed in arterial endothelium. Genes
Dev 2000;14:1313^8.
36. Hellstrom M, Kalen M, Lindahl P, Abramsson
A, Betsholtz C. Role of PDGF-B and PDGFR-h
in recruitment of vascular smooth muscle cells
and pericytes during embryonic blood vessel for-
mation in the mouse. Development 1999;126:
3047^55.
37. Lindahl P, Johansson BR, Leveen P, Betsholtz C.
Pericyte loss and microaneurysm formation in PDGF-
B-deficient mice. Science1997;277:242^5.
38. Sweeney C, Morrow D, Birney YA, et al. Notch 1
and 3 receptors modulate vascular smooth muscle
cell growth, apoptosis and migration via a CBF-1/
RBP-Jk dependent pathway. FASEB J 2004;18:
1421^3.
39. Gee MS, ProcopioWN, Makonnen S, et al. Tumor
vessel development and maturation impose limits on
the effectiveness of anti-vascular therapy. AmJPathol
2003;162:183^93.
40. Abramsson A, Berlin O, Papayan H, et al. Analysis
of mural cell recruitment to tumor vessels. Circulation
2002;105:112^7.
41. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E.
Selective ablation of immature blood vessels in estab-
lished human tumors follows vascular endothelial
growth factor withdrawal. J Clin Invest 1999;103:
159^65.
42.Williams CK, Li JL, Murga M, Harris AL,Tosato G.
Upregulation of the Notch ligand Delta-like 4 inhibits
VEGF-induced endothelial cell function. Blood 2006;
107:931^9.
43.Uyttendaele H, HoJ, RossantJ, KitajewskiJ.Vascu-
lar patterning defects associated with expression of
activatedNotch4 in embryonic endothelium. ProcNatl
Acad Sci US A 2001;98:5643^8.
44. Krebs LT, XueY, Norton CR, et al. Notch signaling is
essential for vascular morphogenesis in mice. Genes
Dev 2000;14:1343^52.
Human Cancer Biology
www.aacrjournals.orgClin Cancer Res 2006;12(16) August15, 2006 4844
